首頁 > 市場調查報告書 > 製藥

消化器

大腸激躁症治療市場規模、佔有率和成長分析：按藥物類別、疾病類型、治療方法、給藥途徑、分銷管道、最終用戶和地區分類－2026-2033年產業預測

市場調查報告書

商品編碼

2068964

大腸激躁症治療市場規模、佔有率和成長分析：按藥物類別、疾病類型、治療方法、給藥途徑、分銷管道、最終用戶和地區分類－2026-2033年產業預測

Irritable Bowel Syndrome Treatment Market Size, Share, and Growth Analysis, By Drug Class, By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel, By End-User, By Region - Industry Forecast 2026-2033

出版日期: 2026年06月16日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球大腸激躁症(IBS) 治療市場價值為 38 億美元，預計到 2025 年將成長至 41.1 億美元，到 2033 年將成長至 77.2 億美元，預測期（2026-2033 年）複合年成長率為 8.2%。

全球大腸激躁症(IBS) 治療市場主要受功能性胃腸疾病盛行率上升和患者認知度提高的推動，這使得以往診斷率低下的疾病轉變為具有重要治療潛力的領域。該市場涵蓋多種治療方法，包括處方藥、非處方藥、以微生物組為中心的療法和行為療法。從症狀治療轉向低FODMAP飲食和腸腦軸調變器標靶治療策略，清晰地展現了該領域的發展演變。關鍵的成長要素包括標靶治療和診斷技術的創新，以及遠端醫療和症狀追蹤應用程式的普及，這些都有助於提高治療依從性和療效。此外，人工智慧正透過利用患者數據制定個人化治療方案，革新個人化醫療，進一步拓展這一不斷發展領域的商業性機會。

全球大腸激躁症治療市場促進因素

隨著人們對腸道菌叢的關注度不斷提高，我們對大腸激躁症生理學的理解也不斷加深，這為發現創新治療標靶鋪平了道路。這些科學進展刺激了投資，促進了產學合作，並推動了基礎研究向新型候選藥物的轉化。對潛在機制的深入理解使得我們能夠開發出不僅關注緩解症狀，而且著眼於疾病根本原因的治療方法。因此，這些進展豐富了開發平臺，並擴大了治療選擇範圍，以滿足患者的多樣化需求。

全球大腸激躁症治療市場面臨的限制因素

由於新治療方法研發、臨床開發和法規核准高成本，全球大腸激躁症)的治療面臨許多挑戰。這些經濟障礙會阻礙投資，尤其是在大腸激躁症這種症狀多元的疾病領域。漫長的研發週期以及對嚴格控制的臨床試驗（需設定明確的終點指標）的需求，增加了申辦方（尤其是中小企業）的風險感知，這可能會阻礙新治療方法的進展。此外，不斷飆升的研發成本會導致定價壓力和健保報銷困難，最終限制市場滲透率，並延緩患者獲得創新治療方法的時間。

全球大腸激躁症治療市場趨勢

全球大腸激躁症(IBS) 治療市場正經歷著向個人化治療的顯著轉變，這主要得益於對患者分層和個別化介入的高度重視。先進的生物標記識別和症狀表現型分析技術的出現，使得治療方法的精準匹配成為可能，從而製定出更有效、更個人化的治療方案。伴隨診斷和整合式醫療模式的出現，進一步改善了患者的治療效果，也為此轉變提供了有力支持。隨著製藥公司專注於分層臨床開發和強力的實證醫學證據，保險公司和臨床醫生也越來越支持能夠改善症狀管理和提升患者整體滿意度的個人化治療方案。這一趨勢正為針對特定患者群體的創新生技藥品、小分子藥物和聯合治療鋪平道路。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家

競爭資訊

前五大公司對比
主要公司2025年的市場定位
主要市場公司採取的策略
近期市場趨勢
企業市場占有率分析，2025 年
主要公司的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）

主要公司簡介

AbbVie Inc.
Takeda Pharmaceutical Company Limited
Ironwood Pharmaceuticals
Ardelyx Inc.
Bausch Health Companies Inc.
Pfizer Inc.
AstraZeneca plc
GlaxoSmithKline plc
Johnson & Johnson
Novartis AG
Astellas Pharma Inc.
Sebela Pharmaceuticals
Mallinckrodt Pharmaceuticals
Lexicon Pharmaceuticals
Salix Pharmaceuticals
Synthetic Biologics
Theriva Biologics
Sanofi
Teva Pharmaceutical Industries
Allergan（AbbVie）

結論與建議

簡介目錄

Product Code: SQMIG35I2830

Global Irritable Bowel Syndrome Treatment Market size was valued at USD 3.8 Billion in 2024 and is poised to grow from USD 4.11 Billion in 2025 to USD 7.72 Billion by 2033, growing at a CAGR of 8.2% during the forecast period (2026-2033).

The global market for irritable bowel syndrome (IBS) treatment is significantly driven by the increasing incidence of functional gastrointestinal disorders and heightened patient awareness, transforming a previously underdiagnosed condition into a prominent therapeutic opportunity. This market includes a diverse range of treatments such as prescription medications, over-the-counter solutions, microbiome-focused therapies, and behavioral interventions. The shift from symptomatic management to targeted strategies, like low-FODMAP diets and gut-brain axis modulators, underscores the sector's evolution. Key growth factors include innovation in targeted therapies and diagnostics, bolstered by the integration of telemedicine and symptom-tracking apps that enhance adherence and outcomes. Additionally, AI is revolutionizing personalized care by using patient data to create tailored treatment plans, further expanding commercial opportunities within this evolving landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Irritable Bowel Syndrome Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Irritable Bowel Syndrome Treatment Market Segments Analysis

Global irritable bowel syndrome treatment market is segmented by drug class, disease type, treatment type, route of administration, distribution channel, end-user and region. Based on drug class, the market is segmented into Antispasmodics, Laxatives, Antidiarrheals, Antidepressants and Others. Based on disease type, the market is segmented into IBS with Constipation (IBS-C), IBS with Diarrhea (IBS-D) and Mixed IBS (IBS-M). Based on treatment type, the market is segmented into Pharmacological Treatments, Dietary Supplements & Probiotics and Psychological Therapies. Based on route of administration, the market is segmented into Oral and Injectable. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on end-user, the market is segmented into Hospitals, Clinics and Homecare. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Irritable Bowel Syndrome Treatment Market

The growing emphasis on the gut microbiome has led to a deeper understanding of the pathophysiology of irritable bowel syndrome, paving the way for the identification of innovative therapeutic targets. This evolving scientific landscape encourages both investment and collaboration between academia and the industry, facilitating the transformation of fundamental research into new treatment candidates. Enhanced insights into the underlying mechanisms allow for the creation of therapies that focus on the root causes of the disease rather than merely alleviating symptoms. As a result, this progress enriches the development pipeline and expands the range of treatment options available to cater to the varied needs of patients.

Restraints in the Global Irritable Bowel Syndrome Treatment Market

The global landscape of irritable bowel syndrome treatment faces considerable obstacles due to the high costs linked to the discovery, clinical development, and regulatory approval of new therapies. These financial barriers can deter investment, especially for disorders with diverse symptoms like irritable bowel syndrome. Extended development timelines and the necessity for rigorously controlled clinical trials with established endpoints increase the perceived risks for sponsors, particularly smaller firms, potentially hindering the advancement of new treatments. Additionally, elevated development costs can lead to pricing pressures and difficulties in securing reimbursement, ultimately limiting market penetration and delaying access to innovative therapies for patients.

Market Trends of the Global Irritable Bowel Syndrome Treatment Market

The Global Irritable Bowel Syndrome (IBS) Treatment market is witnessing a significant trend toward personalized therapy, driven by a strong focus on patient stratification and tailored interventions. The emergence of advanced biomarker identification and symptom phenotyping facilitates precise therapeutic matching, enabling more effective and individualized treatment plans. This shift is supported by companion diagnostics and integrated care models that enhance patient outcomes. As manufacturers concentrate on stratified clinical development and robust evidence generation, payers and clinicians increasingly endorse personalized approaches that improve both symptom management and overall patient satisfaction. This trend opens avenues for innovative biologics, small molecules, and combination therapies targeting specific patient segments.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index 2025
PESTEL Analysis
Regulatory Landscape
Value Chain Analysis
Case Studies
Technology Assessment
Customer & Buying Criteria Analysis
Pipeline Analysis
Disease Epidemiology

Global Irritable Bowel Syndrome Treatment Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Antispasmodics
Laxatives
Antidiarrheals
Antidepressants
Others

Global Irritable Bowel Syndrome Treatment Market Size by Disease Type & CAGR (2026-2033)

Market Overview
IBS with Constipation (IBS-C)
IBS with Diarrhea (IBS-D)
Mixed IBS (IBS-M)

Global Irritable Bowel Syndrome Treatment Market Size by Treatment Type & CAGR (2026-2033)

Market Overview
Pharmacological Treatments
Dietary Supplements & Probiotics
Psychological Therapies

Global Irritable Bowel Syndrome Treatment Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Injectable

Global Irritable Bowel Syndrome Treatment Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Irritable Bowel Syndrome Treatment Market Size by End-User & CAGR (2026-2033)

Market Overview
Hospitals
Clinics
Homecare

Global Irritable Bowel Syndrome Treatment Market Size & CAGR (2026-2033)

North America (Drug Class, Disease Type, Treatment Type, Route of Administration, Distribution Channel, End-User)
- US
- Canada
Europe (Drug Class, Disease Type, Treatment Type, Route of Administration, Distribution Channel, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Disease Type, Treatment Type, Route of Administration, Distribution Channel, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Disease Type, Treatment Type, Route of Administration, Distribution Channel, End-User)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Disease Type, Treatment Type, Route of Administration, Distribution Channel, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ironwood Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ardelyx Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sebela Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mallinckrodt Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lexicon Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Salix Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Synthetic Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Theriva Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allergan (AbbVie)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments